Skip to main content
Midas Edge

Praxis Precision Medicines Inc

For the period ended Dec 31, 2023. Filed Mar 5, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 5, 2024

PRAX$337.59+1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

(Amounts in thousands, except share data)

Common Stock1 · AdditionalPaid-InCapital · AccumulatedDeficit · Accumulated Other Comprehensive Loss · TotalStockholders’Equity
Shares · Amount
Balance at December 31, 20223,292,163$5$606,918$(530,644)$(173)$76,106
Stock-based compensation expense——7,593——7,593
Issuance of common stock from at-the-market public offerings, net of issuance costs560,253118,095——18,096
Vesting of restricted stock units11,516—————
Shares withheld for taxes for vesting of restricted stock units(2,875)—(127)——(127)
Issuance of common stock upon exercise of stock options2,970—101——101
Change in unrealized loss on marketable securities, net of tax————154154
Net loss———(37,455)—(37,455)
Balance at March 31, 20233,864,027$6$632,580$(568,099)$(19)$64,468
Stock-based compensation expense——5,775——5,775
Issuance of common stock from follow-on public offering and accompanying pre-funded warrants, net of underwriting discounts, commissions and offering costs of $4,4844,296,646663,433——63,439
Issuance of common stock from at-the-market public offerings, net of issuance costs392,54116,031——6,032
Issuance of common stock under employee stock purchase plan15,663—208——208
Vesting of restricted stock units720—————
Shares withheld for taxes for vesting of restricted stock units(249)—(4)——(4)
Change in unrealized loss on marketable securities, net of tax————1919
Net loss———(34,312)—(34,312)
Balance at June 30, 20238,569,348$13$708,023$(602,411)$—$105,625
Stock-based compensation expense——5,763——5,763
Vesting of restricted stock units233—————
Shares withheld for taxes for vesting of restricted stock units(70)—(1)——(1)
Issuance of common stock upon exercise of stock options311—1——1
Net loss———(24,632)—(24,632)
Balance at September 30, 20238,569,822$13$713,786$(627,043)$—$86,756
Stock-based compensation expense——5,726——5,726
Issuance of common stock under employee stock purchase plan9,027—106——106
Issuance of common stock from at-the-market public offerings, net of issuance costs of $123212,453—3,964——3,964
Vesting of restricted stock units824—————
Shares withheld for taxes for vesting of restricted stock units(249)—(5)——(5)
Net loss———(26,878)—(26,878)
Balance at December 31, 20238,791,877$13$723,577$(653,921)$—$69,669

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (continued)

(Amounts in thousands, except share data)

Common Stock1 · AdditionalPaid-InCapital · AccumulatedDeficit · Accumulated Other Comprehensive Loss · TotalStockholders’Equity
Shares · Amount
Balance at December 31, 20213,020,034$5$567,598$(316,615)$(176)$250,812
Stock-based compensation expense——7,886——7,886
Issuance of common stock from at-the-market public offerings4,694—1,368——1,368
Vesting of restricted stock units5,408—————
Shares withheld for taxes for vesting of restricted stock units(1,190)—(230)——(230)
Issuance of common stock upon exercise of stock options4,818—333——333
Change in unrealized loss on marketable securities, net of tax————(430)(430)
Net loss———(68,717)—(68,717)
Balance at March 31, 20223,033,764$5$576,955$(385,332)$(606)$191,022
Stock-based compensation expense——7,611——7,611
Issuance of common stock under employee stock purchase plan3,443—454——454
Vesting of restricted stock units424—————
Shares withheld for taxes for vesting of restricted stock units(148)—(17)——(17)
Issuance of common stock upon exercise of stock options876—67——67
Change in unrealized loss on marketable securities, net of tax————(74)(74)
Net loss———(60,194)—(60,194)
Balance at June 30, 20223,038,359$5$585,070$(445,526)$(680)$138,869
Stock-based compensation expense——6,730——6,730
Issuance of common stock from at-the-market public offerings, net of issuance costs of $10973,667—2,962——2,962
Vesting of restricted stock units354—————
Shares withheld for taxes for vesting of restricted stock units(109)—(6)——(6)
Issuance of common stock upon exercise of stock options12,016—409——409
Change in unrealized loss on marketable securities, net of tax————144144
Net loss———(43,945)—(43,945)
Balance at September 30, 20223,124,287$5$595,165$(489,471)$(536)$105,163
Stock-based compensation expense——6,366——6,366
Issuance of common stock under employee stock purchase plan5,982—163——163
Issuance of common stock from at-the-market public offerings161,323—5,231——5,231
Vesting of restricted stock units800—————
Shares withheld for taxes for vesting of restricted stock units(229)—(7)——(7)
Issuance of common stock upon exercise of stock options——————
Change in unrealized loss on marketable securities, net of tax————363363
Net loss———(41,173)—(41,173)
Balance at December 31, 20223,292,163$5$606,918$(530,644)$(173)$76,106
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.